Achillion Pharmaceuticals Inc. today announced that the interim results of its ongoing phase 2a study, conducted by Alios BioPharma, part of the Janssen Pharmaceutical Companies, will be presented at the European Association for the Study of the Liver (EASL) Special Conference. Read More »

Phase III study shows up to 40 percent reduction in seizures in study participants. Read More »

Naldemedine found effective in treating OIC in a year-long Phase III study. Read More »

CVS Health has announced the launch of Project Health, its free health services campaign that is held on an annual basis. Read More »

Amgen has announced that the data from studies involving romosozumab and Prolia will be presented at the Annual Meeting of American Society for Bone and Mineral Research (ASBMR) on Sept. 16-19 in Atlanta, Georgia. Read More »

Imprimis Pharmaceuticals this week announced that it has launched its new patient assistance program, Imprimis Cares Access Network (ICAN). Read More »

HSRx Biopharmaceutical has announced that HSRx 431, the company’s broad-spectrum antiviral drug candidate that is administered orally, has shown that it is effective against the Zika virus. Read More »

Sangamo BioSciences Inc. recently announced that SB-FIX has been granted orphan drug designation by the U.S. Food and Drug Administration (FDA). Read More »

Avara Pharmaceuticals Services Inc. recently announced that it has come to terms on an agreement for the acquisition of a manufacturing facility from AstraZeneca located in Avlon, Avonmouth, England. Read More »

Oasima Pharmaceutical AB has announced that Fredrik Gynnerstedt has been appointed the company’s new CFO. Read More »

PharmRight and Zipit work together to help patients manage complicated medication regimes. Read More »

Array BioPharma announced last week that its New Drug Application (NDA) for binimetinib has been accepted by the U.S. Food and Drug Administration (FDA). Read More »

Amgen and Servier last week announced that their cardiovascular collaboration has seen an advancement due to Servier deciding to exercise its option for the commercialization of omecamtiv mecarbil in Europe for chronic heart failure. Read More »

Available in wide range of fluorochromes for research use only. Read More »

Laboratorios Salvat S.A.and Arbor Pharmaceuticals LLC recently partnered on the launch of OTOVEL (ciprofloxacin 0.3% and fluocinolone acetonide 0.025%) otic solution. Read More »

Vifor Pharma, which is owned by Galenica, will be combined with Relypsa to form an important cardio-renal care provider in the United States. Read More »

The decision by the FDA was done under accelerated approval with continued approval dependent on consequent trials verifying the clinical benefit of BLINCYTO. Read More »

If drug manufacturers ever wonder whether they have a collective image problem, the answer is yes, according to a recent Gallup poll. Read More »

The U.S. Food and Drug Administration (FDA) has granted orphan drug designation to Catalyst Pharmaceuticals Inc. for Firdapse to treat myasthenia gravis (MG).e Read More »

Mylan NV yesterday announced that its inter-parties review (IPR) proceeding in regard to U.S. Patent No. 8,969,302, which is owned by Yeda Research & Development Co. and licensed to Teva Pharmaceuticals, was ruled in its favor of by the U.S. Patent and Trademark Office (PTO) and found unpatentable. Read More »